Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Pharmacol Exp Ther
2022 Nov 01;3832:157-171. doi: 10.1124/jpet.122.001354.
Show Gene links
Show Anatomy links
Differential Activation and Desensitization States Promoted by Noncanonical α7 Nicotinic Acetylcholine Receptor Agonists.
Stokes C
,
Camacho-Hernandez GA
,
Thakur GA
,
Wu X
,
Taylor P
,
Papke RL
.
???displayArticle.abstract???
A series of dipicolyl amine pyrimidines (DPPs) were previously identified as potential α7 agonists by means of a calcium influx assay in the presence of the positive allosteric modulator (PAM) 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596). The compounds lack the quaternary or strongly basic nitrogens of typical nicotinic agonists. Although differing in structure from typical nicotinic agonists, based on crystallographic data with the acetylcholine binding protein, they appeared to engage the site shared by such typical orthosteric agonists. Using oocytes expressing human α7 receptors, we found that the DPPs were efficacious activators of the receptor, with currents showing rapid desensitization characteristic of α7 receptors. However, we note that the rate of recovery from this desensitization depends strongly on structural features within the DPP family. Although the activation of receptors by DPP was blocked by the competitive antagonist methyllycaconitine (MLA), MLA had no effect on the DPP-induced desensitization, suggesting multiple modes of DPP binding. As expected, the desensitized conformational states could be reactivated by PAMs. Mutants made insensitive to acetylcholine by the C190A mutation in the agonist binding site were weakly activated by DPPs. The observation that activation of C190A mutants by the DPP compounds was resistant to the allosteric antagonist (-)cis-trans-4-(2,3,5,6-tetramethylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide supports the hypothesis that the activity of these noncanonical agonists in the orthosteric binding sites was not entirely dependent on the classic epitopes controlling activation by typical agonists and that perhaps they may access alternative modes for promoting the conformational changes associated with activation and desensitization. SIGNIFICANCE STATEMENT: This study reports a family of nicotinic acetylcholine receptor agonists that break the rules about what the structure of a nicotinic acetylcholine receptor agonist should be. It shows that the activity of these noncanonical agonists in the orthosteric binding sites is not dependent on the classical epitopes controlling activation by typical agonists and that through different binding poses, they promote unique conformational changes associated with receptor activation and desensitization.
Aickin,
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
1996, Pubmed
Aickin,
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
1996,
Pubmed
Alkondon,
Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist.
1992,
Pubmed
Andersen,
Exploring the positive allosteric modulation of human α7 nicotinic receptors from a single-channel perspective.
2016,
Pubmed
Bagdas,
New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.
2018,
Pubmed
Beers,
Structure and activity of acetylcholine.
1970,
Pubmed
Bertrand,
Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors.
2015,
Pubmed
Bodnar,
Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.
2005,
Pubmed
Bouzat,
Molecular function of α7 nicotinic receptors as drug targets.
2018,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Briggs,
Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
2009,
Pubmed
,
Xenbase
Camacho-Hernandez,
Synthesis, Pharmacological Characterization, and Structure-Activity Relationships of Noncanonical Selective Agonists for α7 nAChRs.
2019,
Pubmed
,
Xenbase
Camacho-Hernandez,
Lessons from nature: Structural studies and drug design driven by a homologous surrogate from invertebrates, AChBP.
2020,
Pubmed
Gill,
A series of α7 nicotinic acetylcholine receptor allosteric modulators with close chemical similarity but diverse pharmacological properties.
2012,
Pubmed
,
Xenbase
Gill,
Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
2011,
Pubmed
,
Xenbase
Gulsevin,
In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling.
2020,
Pubmed
Gulsevin,
Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site.
2019,
Pubmed
,
Xenbase
Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase
Hibbs,
Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor.
2009,
Pubmed
Hurst,
A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.
2005,
Pubmed
,
Xenbase
Jia,
Nicotine trapping causes the persistent desensitization of alpha4beta2 nicotinic receptors expressed in oocytes.
2003,
Pubmed
,
Xenbase
Jones,
Nicotinic receptors in the brain: correlating physiology with function.
1999,
Pubmed
KATZ,
A study of the desensitization produced by acetylcholine at the motor end-plate.
1957,
Pubmed
Kabbani,
Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.
2018,
Pubmed
Kaczanowska,
Substituted 2-Aminopyrimidines Selective for α7-Nicotinic Acetylcholine Receptor Activation and Association with Acetylcholine Binding Proteins.
2017,
Pubmed
King,
A G protein-coupled α7 nicotinic receptor regulates signaling and TNF-α release in microglia.
2017,
Pubmed
King,
Ionotropic and Metabotropic Mechanisms of Allosteric Modulation of α7 Nicotinic Receptor Intracellular Calcium.
2018,
Pubmed
Levin,
AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats.
1999,
Pubmed
Lewis,
Bidirectional Regulation of Aggression in Mice by Hippocampal Alpha-7 Nicotinic Acetylcholine Receptors.
2018,
Pubmed
Miller,
Allosterically Potentiated α7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium.
2020,
Pubmed
,
Xenbase
Mineur,
Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice.
2018,
Pubmed
Noviello,
Structure and gating mechanism of the α7 nicotinic acetylcholine receptor.
2021,
Pubmed
Papke,
Tricks of perspective: insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization.
2010,
Pubmed
,
Xenbase
Papke,
The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor.
2015,
Pubmed
,
Xenbase
Papke,
Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of α7 nAChR.
2020,
Pubmed
Papke,
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.
2021,
Pubmed
Papke,
Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling.
2020,
Pubmed
Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase
Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase
Papke,
Cysteine accessibility analysis of the human alpha7 nicotinic acetylcholine receptor ligand-binding domain identifies L119 as a gatekeeper.
2011,
Pubmed
,
Xenbase
Pieschl,
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
2017,
Pubmed
Pismataro,
Stable desensitization of α7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site.
2021,
Pubmed
,
Xenbase
Pismataro,
Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation.
2020,
Pubmed
,
Xenbase
Quadri,
The Antinociceptive and Anti-Inflammatory Properties of the α7 nAChR Weak Partial Agonist p-CF3 N,N-diethyl-N'-phenylpiperazine.
2018,
Pubmed
,
Xenbase
Rang,
On the mechanism of desensitization at cholinergic receptors.
1970,
Pubmed
Rang,
The relationship between desensitization and the metaphilic effect at cholinergic receptors.
1970,
Pubmed
Sheridan,
The ensemble approach to distance geometry: application to the nicotinic pharmacophore.
1986,
Pubmed
Sine,
Functional consequences of agonist-mediated state transitions in the cholinergic receptor. Studies in cultured muscle cells.
1979,
Pubmed
Sine,
The relationship between agonist occupation and the permeability response of the cholinergic receptor revealed by bound cobra alpha-toxin.
1980,
Pubmed
Sine,
Relationship between reversible antagonist occupancy and the functional capacity of the acetylcholine receptor.
1981,
Pubmed
Sullivan,
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.
1995,
Pubmed
Séguéla,
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
1993,
Pubmed
,
Xenbase
Thakur,
Expeditious synthesis, enantiomeric resolution, and enantiomer functional characterization of (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an allosteric agonist-positive allosteric modulator of α7 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Thomsen,
The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
2012,
Pubmed
Tracey,
Physiology and immunology of the cholinergic antiinflammatory pathway.
2007,
Pubmed
Tønder,
An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by.
2001,
Pubmed
Uteshev,
Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors.
2002,
Pubmed
Wang,
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.
2003,
Pubmed
Williams,
Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.
2012,
Pubmed
,
Xenbase
Williams,
Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.
2011,
Pubmed
,
Xenbase
Young,
Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.
2008,
Pubmed
,
Xenbase
de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed